Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock

Key Points

• Immuneering Corporation Director Peter Feinberg purchased 7,500 shares of stock at an average price of $6.67, increasing his ownership by 5.02% to a total of 156,766 shares valued at over $1 million.
• The company's stock, which has a market cap of $258.36 million, saw recent trading at $6.22 with a 1-year low of $1.10 and high of $10.08.
• Several research analysts maintain a consensus rating of "Hold" for Immuneering with a price target of $16.40, while some have upgraded the stock's rating to "buy".

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg acquired 7,500 shares of the company's stock in a transaction on Friday, October 3rd. The shares were acquired at an average price of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the acquisition, the director directly owned 156,766 shares in the company, valued at $1,045,629.22. The trade was a 5.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Peter Feinberg also recently made the following trade(s):

• On Tuesday, September 30th, Peter Feinberg purchased 7,500 shares of Immuneering stock. The shares were bought at an average cost of $7.03 per share, with a total value of $52,725.00.
• On Monday, September 29th, Peter Feinberg purchased 5,000 shares of Immuneering stock. The stock was bought at an average price of $7.18 per share, with a total value of $35,900.00.

Immuneering Price Performance

IMRX traded down $0.07 during trading on Tuesday, hitting $6.22. The company had a trading volume of 1,201,829 shares, compared to its average volume of 1,468,985. The company has a market cap of $258.36 million, a PE ratio of -3.28 and a beta of 0.47. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08. The business has a 50-day moving average of $5.72 and a 200-day moving average of $3.43.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). Research analysts forecast that Immuneering Corporation will post -1.86 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on IMRX shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Immuneering in a research report on Saturday, September 27th. Chardan Capital increased their price objective on shares of Immuneering from $13.00 to $20.00 and gave the company a "buy" rating in a report on Friday, September 26th. Needham & Company LLC increased their price target on Immuneering from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Mizuho lifted their price target on Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Wednesday, June 18th. Finally, Oppenheimer upped their price objective on Immuneering from $21.00 to $30.00 and gave the company an "outperform" rating in a report on Thursday, September 25th. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Immuneering currently has a consensus rating of "Hold" and a consensus price target of $16.40.

Institutional Trading of Immuneering

A number of hedge funds have recently bought and sold shares of IMRX. Kingsview Wealth Management LLC acquired a new position in Immuneering in the 2nd quarter worth approximately $47,000. Jane Street Group LLC purchased a new stake in shares of Immuneering in the first quarter valued at $32,000. XTX Topco Ltd acquired a new stake in shares of Immuneering in the second quarter worth $90,000. Flower City Capital purchased a new position in shares of Immuneering during the second quarter valued at $108,000. Finally, Two Sigma Investments LP raised its position in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after buying an additional 10,126 shares during the period. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.